Effect and Safety of Meropenem–Vaborbactam versus Best-Available Therapy in Patients with Carbapenem-Resistant Enterobacteriaceae Infections: The TANGO II Randomized Clinical Trial [PDF]
Infectious Diseases and Therapy, 2018 Introduction Treatment options for carbapenem-resistant Enterobacteriaceae (CRE) infections are limited and CRE infections remain associated with high clinical failure and mortality rates, particularly in vulnerable patient populations.
Richard G. Wunderink +22 more
doaj +5 more sources
Outcomes and Predictors of Mortality in Patients With KPC-Kp Infections Treated With Meropenem Vaborbactam: An Observational Multicenter Study. [PDF]
Open Forum Infect DisBackground Meropenem-vaborbactam is a recent and promising option for the treatment of KPC-producing Klebsiella pneumoniae (KPC-Kp) infections, including those resistant to ceftazidime-avibactam.Methods We conducted a retrospective analysis of ...
Tumbarello M +34 more
europepmc +17 more sources
Meropenem-Vaborbactam Activity against U.S. Multidrug-Resistant Enterobacterales Strains, Including Carbapenem-Resistant Isolates [PDF]
Microbiology Spectrum, 2023 Carbapenems are a common first-line therapy for serious Gram-negative infections, but carbapenem-resistant Enterobacterales (CRE) isolates have become an urgent health concern. Klebsiella pneumoniae serine carbapenemases (KPCs) now have been disseminated
Dee Shortridge +2 more
doaj +2 more sources
Microbiological, Clinical, and PK/PD Features of the New Anti-Gram-Negative Antibiotics: β-Lactam/β-Lactamase Inhibitors in Combination and Cefiderocol—An All-Inclusive Guide for Clinicians [PDF]
Pharmaceuticals, 2022 Bacterial resistance mechanisms are continuously and rapidly evolving. This is particularly true for Gram-negative bacteria. Over the last decade, the strategy to develop new β-lactam/β-lactamase inhibitors (BLs/BLIs) combinations has paid off and ...
Luigi Principe +11 more
doaj +3 more sources
Infectious Diseases and Therapy, 2020 Plain Language Summary Meropenem-vaborbactam is a new combination antibiotic that was designed specifically for efficacy against bacteria that produce the Klebsiella pneumoniae carbapenemase (KPC) enzyme, which enables resistance to beta-lactam ...
Tanaya Bhowmick, Melvin P. Weinstein
doaj +2 more sources
In vitro activity of meropenem-vaborbactam combinations and eravacycline against carbapenem-resistant Acinetobacter baumannii [PDF]
Scientific ReportsTreatment of carbapenem-resistant Acinetobacter baumannii (CRAB) presents a growing clinical challenge. This study evaluated the in vitro efficacy of eravacycline and the potential synergistic activity of meropenem-vaborbactam in combination with either ...
Amira H. El-Ashry +4 more
doaj +2 more sources
Clinical Evaluation of Meropenem-Vaborbactam Combination for the Treatment of Urinary Tract Infection: Evidence to Date [PDF]
Infection and Drug Resistance, 2023 Fischer Herald,1 Rodrigo M Burgos1,2 1Department of Pharmacy Practice, College of Pharmacy, University of Illinois Chicago, Chicago, IL, USA; 2Department of Medicine, College of Medicine, University of Illinois Chicago, Chicago, IL, USACorrespondence ...
Herald F, Burgos RM
doaj +2 more sources
Stability Studies of Antipseudomonal Beta Lactam Agents for Outpatient Therapy [PDF]
Pharmaceutics, 2023 Outpatient parenteral antimicrobial therapy (OPAT) is a useful treatment strategy against Pseudomonas aeruginosa and other multidrug-resistant bacteria.
Beatriz Fernández-Rubio +9 more
doaj +3 more sources
National Cohort of Compassionate Use of Meropenem–Vaborbactam: No Benefit over Meropenem for Pseudomonas aeruginosa [PDF]
AntibioticsBackground: Meropenem–vaborbactam (MEM-VAB) is a novel carbapenem-beta-lactamase-inhibitor combination that demonstrates activity against carbapenem-resistant (CR) Gram-negative bacteria, and more specifically KPC-producers, since vaborbactam is an ...
Aurélien Dinh +24 more
doaj +2 more sources
In vitro-obtained meropenem-vaborbactam resistance mechanisms among clinical Klebsiella pneumoniae carbapenemase-producing K. pneumoniae isolates [PDF]
Journal of Global Antimicrobial Resistance, 2023 : Objectives: A novel ß-lactam-β-lactamase inhibitor (BLBI), meropenem (MEM), combined with the boronate-based inhibitor vaborbactam (VAB), has recently been introduced for the treatment of infections caused by Klebsiella pneumoniae carbapenemase (KPC ...
Jacqueline Findlay +2 more
doaj +3 more sources